Can I Take Vitamin B12 with NMN or NR (Nicotinamide Mononucleotide / Riboside)?

What Are NMN and NR, and Why Do People Stack Them with B12?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme required for cellular energy production, DNA repair, and sirtuin activity. Oral NMN and NR raise blood and tissue NAD+ levels in human subjects, a finding confirmed in multiple randomized controlled trials [1,2]. Vitamin B12, meanwhile, is a water-soluble vitamin that supports myelin synthesis, red blood cell formation, and the methylation cycle. People combine them because both are popular in longevity and metabolic optimization protocols, and because practitioners sometimes screen for B12 deficiency in the same patients who ask about NAD precursors.

How NMN and NR Raise NAD+ Levels

After oral ingestion, NR is absorbed intact across the intestinal epithelium and converted intracellularly to NMN, then to NAD+ via the Preiss-Handler and salvage pathways [3]. NMN bypasses this first step and is phosphorylated directly to NAD+ by NMNAT enzymes. A 2020 human pharmacokinetic study by Irie et al. (N=10) showed that a single 100 to 500 mg NMN dose raised plasma NMN within 2 to 3 hours without serious adverse effects [1]. A 2023 randomized trial by Igarashi et al. (N=30) demonstrated that 250 mg/day NMN over 12 weeks increased NAD+ metabolite levels in peripheral blood mononuclear cells [4].

What Vitamin B12 Does in the Same Metabolic Context

B12 (as methylcobalamin or adenosylcobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase. These enzymes are part of the one-carbon cycle that also involves folate. None of these enzymatic steps overlap with the NAD+ biosynthesis cascade. The two pathways share no common enzyme, transporter, or metabolic intermediate in human biochemistry [5].

Is There a Pharmacokinetic Interaction Between B12 and NMN or NR?

No pharmacokinetic interaction has been identified. The absorption, distribution, metabolism, and excretion profiles of these two nutrients are entirely separate.

Absorption Pathways

Oral B12 at physiologic doses (<2 mcg) is absorbed in the terminal ileum via intrinsic factor. At supplemental doses above roughly 1,000 mcg, passive diffusion accounts for about 1% absorption independent of intrinsic factor [6]. NMN and NR are absorbed higher in the gastrointestinal tract, primarily in the small intestine, through distinct nucleoside transporters and phosphatases. There is no competitive binding at shared receptors.

Metabolism and Clearance

B12 circulates bound to transcobalamin II and haptocorrin; excess is renally cleared. NMN is rapidly converted intracellularly to NAD+ and downstream metabolites including NAAD and MeNAM, then excreted as methylated pyridine derivatives in urine [7]. None of these metabolites interfere with B12 tissue uptake or cellular retention. The Natural Medicines database (accessed via professional subscription) lists no interaction between cobalamin forms and NAD precursors.

Is There a Pharmacodynamic Interaction?

No pharmacodynamic antagonism or synergism has been reported in human or animal data as of early 2025.

Independent Cellular Targets

NMN and NR act primarily through sirtuin activation (SIRT1, SIRT3), PARP enzyme support, and mitochondrial bioenergetics [3]. B12 acts through methionine synthase and methylmalonyl-CoA mutase. A 2021 trial by Yoshino et al. Published in Science (N=25 post-menopausal women with prediabetes) showed that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity without reporting any effect on cobalamin metabolism [2].

Potential Complementary Effects

Some practitioners propose that optimizing methylation (via B12 and folate) may support NAD+ metabolism indirectly, because NNMT (nicotinamide N-methyltransferase) consumes methyl groups from S-adenosylmethionine when it degrades nicotinamide. A 2020 review in Aging Cell noted that high NAD+ flux could theoretically increase methyl group demand, suggesting that adequate B12 and folate might be advisable alongside long-term NMN use [8]. This remains theoretical and has not been tested in a prospective human trial.

The Real Clinical Issue: Metformin, B12 Depletion, and NMN Users

This is the most clinically meaningful concern when B12 and NMN or NR come up together, and it is frequently missed in competitor articles.

Why Metformin Depletes B12

Metformin impairs B12 absorption by reducing ileal calcium-dependent binding of the intrinsic factor-B12 complex [9]. The effect is dose-dependent and cumulative. A landmark analysis of the UK Biobank and multiple European cohorts found that long-term metformin users had meaningfully lower serum B12 than non-users, with deficiency rates reaching 5.8 to 30% depending on dose and duration [9,10]. The 2022 ADA Standards of Medical Care explicitly state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially those with peripheral neuropathy or anemia" [11].

Where NMN Enters the Picture

NMN is increasingly used in adults with type 2 diabetes and metabolic syndrome, exactly the population most likely to be on metformin. A person taking metformin for glucose control and NMN for metabolic aging may develop B12 deficiency that presents as peripheral neuropathy or macrocytic anemia. Without B12 monitoring, this deficiency can be mistaken for metformin side effects or early diabetic neuropathy. Recognizing the overlap is essential for correct attribution and treatment.

Monitoring Protocol for Metformin Plus NMN Users

The American Diabetes Association recommends checking serum B12 at baseline and annually in metformin users [11]. For patients also taking NMN or NR, HealthRX clinicians apply the following screening approach:

• Check serum B12 at NMN/NR initiation if the patient is also on metformin.
• A serum B12 <300 pg/mL warrants reflex methylmalonic acid (MMA) testing to confirm functional deficiency.
• If MMA is elevated (above 0.4 micromol/L), initiate oral B12 supplementation at 1,000 mcg/day cyanocobalamin or methylcobalamin.
• Recheck serum B12 and MMA at 12 weeks.

Who Else Should Monitor B12 When Starting NMN or NR?

Metformin users are not the only group at risk. Several populations enter NMN and NR protocols with pre-existing B12 insufficiency that supplementation alone may not fully address.

Adults Over 60

Gastric atrophy and reduced parietal cell output lower intrinsic factor production with age. An estimated 6% of adults aged 60 or older are B12-deficient, rising to 20% of those over 80, based on NHANES data analyzed by the NIH Office of Dietary Supplements [12]. These adults are also the primary demographic pursuing NAD precursor therapy.

Vegans and Strict Vegetarians

Plant-based diets provide essentially no bioavailable B12. The Academy of Nutrition and Dietetics recommends routine B12 supplementation for all vegans [13]. A person in this group who adds NMN or NR without checking baseline B12 may be masking a pre-existing deficiency.

People on Proton Pump Inhibitors

PPIs reduce gastric acid output, impairing protein-bound B12 release from food (though not from supplements). Long-term PPI use is associated with lower serum B12 in observational data [14]. Many metabolic health patients use PPIs concurrently with NMN.

Dosing and Timing: Practical Guidance

No mandatory separation window is required. You can take NMN or NR and B12 at the same meal or at different times of day without affecting efficacy or safety for either compound.

Suggested Daily Stack for a Typical Adult

• NMN: 250 to 500 mg oral in the morning (aligns with the doses used in Irie 2020 [1] and Yoshino 2021 [2]).
• Vitamin B12: 500 to 1,000 mcg oral methylcobalamin or cyanocobalamin, any time of day. Sublingual forms may modestly improve absorption in patients with intrinsic factor issues.
• No nutrient competition at absorption sites means simultaneous dosing is acceptable.

What the Human Trial Data Covers

The longest published human NMN trial as of early 2025 ran 12 weeks at 250 mg/day (Igarashi 2023, N=30) [4]. The longest NR trial showing metabolic effects ran 12 weeks at 1,000 mg/day (Elhassan 2019, N=12) [15]. Neither study reported changes in serum B12 as an adverse event or secondary outcome, providing indirect reassurance that short-to-medium-term NMN or NR use does not deplete B12 directly.

Safety Profile of the Combination

Both compounds are well-tolerated at standard doses. NMN and NR have been granted Generally Recognized as Safe (GRAS) status by the FDA for specific formulations, and neither compound carries FDA boxed warnings [16]. Vitamin B12 has no established tolerable upper intake level because excess is renally cleared; toxicity from oral B12 supplementation is not documented in the literature [12].

Reported Adverse Events in NMN/NR Trials

Across published human trials, the most common adverse effects from NMN and NR are mild gastrointestinal complaints (nausea, loose stool) in a minority of participants, typically at doses above 1,000 mg/day [4,15]. No hematologic, neurologic, or B12-related adverse events were attributed to NMN or NR in any published RCT.

Reported Adverse Events from High-Dose B12

Oral B12 even at 5,000 mcg/day produces no documented toxicity. A small number of case reports have associated very high-dose parenteral B12 with acneiform skin reactions, but this is not relevant to oral supplementation at the doses used in longevity protocols [12].

What the Guidelines Say

No major clinical guideline from the Endocrine Society, American College of Physicians, or FDA directly addresses the co-administration of NMN or NR with vitamin B12. This is partly because NMN and NR remain classified as dietary supplements, not regulated drugs, in the United States. The FDA issued a 2022 enforcement letter specifically naming NMN as a substance that had been authorized for investigation as a new drug, which complicates its legal status as a supplement [16]. Clinicians prescribing NMN through telehealth platforms should document informed consent regarding this regulatory ambiguity.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not address NMN or NR but recommends screening for micronutrient deficiencies (including B12) before initiating metabolic interventions in adults with obesity, a framework that applies here [17].

Special Considerations for HealthRX Patients on TRT or HRT

Some HealthRX patients combine testosterone replacement therapy or hormone replacement therapy with NMN and B12. Testosterone does not alter B12 metabolism. Estrogen may modestly increase transcobalamin II binding capacity, which can raise apparent serum B12 without reflecting true tissue repletion, though the clinical significance is minor [18]. Patients on combined hormone therapy who receive a high-normal serum B12 result should not skip MMA testing if neuropathy symptoms are present.